UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/646,391	08/21/2003	Martin Gleave	UBC.P-035	9734
57381 7590 05/01/2007 Marina Larson & Associates, LLC			EXAMINER	
P.O. BOX 4928	_	·	BOWMAN, AMY HUDSON	
DILLON, CO 80435			ART UNIT	PAPER NUMBER
			1635	
			·	
			MAIL DATE	DELIVERY MODE
			05/01/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(a)				
	Application No.	Applicant(s)				
Office Action Summary	10/646,391	GLEAVE ET AL.				
Office Action Summary	Examiner	Art Unit				
Ti- MAN INO DATE of this assessment of the	Amy H. Bowman	1635				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the d	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 05 A	pril 2007.					
2a)⊠ This action is FINAL . 2b)☐ This	· · · · · · · · · · · · · · · · · · ·					
3) Since this application is in condition for allowar	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims		•				
4) Claim(s) 14 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) 2-12 is/are objected to. 8) Claim(s) are subject to restriction and/o						
Application Papers	•					
9) ☐ The specification is objected to by the Examine 10) ☑ The drawing(s) filed on 21 August 2003 is/are: Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Examine 11.	a)⊠ accepted or b)□ objected drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment(s)	A\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	· (PTO 412)				
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D	ate				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal I	Patent Application				

Art Unit: 1635

DETAILED ACTION

Status of Application/Amendment/Claims

Applicant's response filed 4/5/07 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 3/28/07 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 2-12 and 14 are pending in the application.

Applicant's amendments filed on 4/5/07, with respect to the claim rejections under 35 U.S.C. 112, 35 U.S.C. 102 and 35 U.S.C. 103(a) have been fully considered and are persuasive. Therefore, the rejections have been withdrawn. However, the claim objections are still pending and upon further consideration, a new ground(s) of rejection is made in view of the instant claim amendments.

Claim Objections

Claims 2-12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Application/Control Number: 10/646,391

Art Unit: 1635

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 14 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 14 is directed to a method for treatment of melanoma in a mammalian subject comprising the step of administering to the subject a therapeutic agent effective to reduce the amount of clusterin in the melanoma cells, wherein the therapeutic agent is an oligonucleotide targeted to clusterin.

One of ordinary skill in the art would not be able to envisage the genus of what types of oligonucleotides are embraced by the genus of being targeted to clusterin or what relationship is required for the oligonucleotide to be targeted to clusterin.

Applicant has not defined the term "targeted to" and it is not a term of the art. Applicant has not described what relationship is required between the oligonucleotide and clusterin for the oligonucleotide to be "targeted to" clusterin.

Furthermore, the genus of oligonucleotides that meets the broad limitation of being targeted to clusterin embraces aptamers, which have not been described by applicant. Aptamers would reduce the amount of functional clusterin in cells and Application/Control Number: 10/646,391

Art Unit: 1635

applicant has not shown which aptamers would be considered to be "targeted to" clusterin.

Although the specification discloses antisense oligonucleotide and siRNA sequences that are considered to be targeted to clusterin, the specification does not describe any other oligonucleotides that are targeted to clusterin to describe the instant genus of oligonucleotides that have a relationship of being "targeted to" clusterin, as instantly claimed. The skilled artisan would not be able to envisage the instant genus of molecules in the instant method such that the skilled artisan would recognize that the applicant was in possession of the claimed genus at the time of filing. The skilled artisan would not be able to envisage which oligonucleotides would be "targeted to" clusterin without undue experimentation.

<u>Vas-Cath Inc. v. Mahurkar</u>, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See <u>Vas-Cath</u> at page 1116.)

Thus, the instantly claimed invention cannot be said to have been adequately described in a way that would convey with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the claimed invention because the specification does not provide a description of a sufficient number of

Art Unit: 1635

species of types of oligonucleotides or a specific criteria for the oligonucleotide to have to be "targeted to" clusterin as instantly claimed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy H. Bowman whose telephone number is (571) 272-0755.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Schultz can be reached on (571) 272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CAMADA) or 571-272-1000.

JON E. ANGELL, PH.D. PRIMARY EXAMINER Amy H Bowman Examiner Art Unit 1635

AHB